BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress

Core Insights - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for neurological and neurodegenerative disorders, as well as advanced liver disease [1][4] Group 1: Company Developments - BioVie announced two poster presentations at the Advanced Therapeutics in Movement and Related Disorders Congress, scheduled for June 21-25, 2024 [1] - The presentations will include data on bezisterim's impact on motor and non-motor symptoms in Parkinson's disease, showcasing results from a Phase 2a, placebo-controlled study [2][7] - Bezisterim is also being investigated for Alzheimer's disease, with previous studies indicating improved cognition and biomarker levels in treated patients [3][4] Group 2: Drug Candidates - Bezisterim (NE3107) is an orally bioavailable, BBB-permeable insulin-sensitizer that exhibits anti-inflammatory properties and has a low risk of drug-to-drug interactions [9] - The drug candidate is designed to inhibit inflammatory activation linked to neurodegenerative diseases, specifically targeting pathways that lead to neuroinflammation and insulin resistance [4] - BIV201, another drug candidate for liver disease, has received FDA Fast Track status and is being prepared for Phase 3 clinical testing for treating ascites due to chronic liver cirrhosis [4]